共找到 4 条结果
暂无摘要（点击查看详情）
Background: the prevalence of obesity is reaching a pandemic status. The SCALE trials showed that liraglutide 3 mg among people with obesity (PwO) was effective to reduce bodyweight and related complications. The fact that almost two-thirds of patients did not achieve the desired weight loss with the maximum dose of liraglutide made almost mandatory the development of other pharmacological options. The STEP 1-5 trials showed the effectiveness of semaglutide in reducing bodyweight in a dose-dependent manner. Moreover, the STEP 8 trial proved the superiority of semaglutide 2,4 mg/week versus liraglutide 3 mg/daily. We aimed to assess the effects of subcutaneous (s.c.) semaglutide 0.5 mg/weekly compared with s.c. liraglutide 3 mg/daily in PwO on anthropometric parameters in a real world-scenario for 3 months. Methods: we retrospectively evaluated 179 PwO (91.9 % ♀, 45.7 ± 10 years, and 33.3 ± 7 kg/m2) who received treatment with aGLP-1 as add-on therapy to lifestyle interventions. Patients were evaluated at baseline and after 3 months. Ninety-nine patients were prescribed s.c. semaglutide 0.5 mg/weekly with an off-label indication for weight reduction. These patients were compared with 80 patients treated with s.c. liraglutide 3 mg/daily. The main reason for prescribing of s.c. semaglutide was economic. Body composition was evaluated using a bioimpedance device (Tanita MC 580M®). Results: baseline weight was significantly greater with semaglutide compared to liraglutide (97.19 ± 21.09 vs. 90.73 ± 21.88 kg; p < 0.01) as was fat mass (42.43 ± 15.04 vs. 34.84 ± 16.07 kg; p < 0.01), whereas baseline lean mass was lesser among subjects treated with semaglutide (31.62 ± 7.56 vs 45.69 ± 15.51 kg; p < 0.01). PwO experienced a significant reduction in weight using s.c. semaglutide 0.5 mg/weekly (96.67 ± 20.83 vs. 91.44 ± 19.6 kg; p < 0.01) or s.c. liraglutide 3 mg/daily (90.73 ± 21.88 vs. 80.13 ± 18.38 kg; p < 0.01) No significant differences were seen between the amount of weight lost (5.28 ± 4.22 vs 5.72 ± 1.62 kg; p = 0.5) in the two groups. Furthermore, both groups were comparable in fat mass (2.69 ± 5.34 vs 0.96 ± 4.22 kg; p = 0.3) and fat-free mass (0.86 ± 1.63 vs 1.03 ± 0.94 kg; p = 0.07) after 3 months of treatment with both aGLP1. Side effects were gastrointestinal and transient/comparable between groups Conclusions: subcutaneous semaglutide 0.5 mg and subcutaneous liraglutide 3 mg are effective treatments for reducing weight safely among PwO in a real-world scenario at short term and without a negative impact on fat-free mass. Moreover, low doses of semaglutide were similar to liraglutide 3 mg in reducing bodyweight at short term. Introducción: casi dos tercios de los pacientes en tratamiento con 3 mg de liraglutida no lograran los objetivos de pérdida de peso, lo que lleva a la búsqueda de otras opciones farmacológicas. El STEP 8 demostró la superioridad de la semaglutida, 2,4 mg/semana, en comparación con la liraglutida, 3 mg/día. Evaluamos los efectos de 0,5 mg de semaglutida sc semanal en comparación con 3 mg de liraglutida/día en personas con obesidad (PwO) sobre los parámetros antropométricos en la vida real durante 3 meses. Métodos: 179 PwO (91,9 % mujeres, 45,7 ± 10 años e IMC de 33,3 ± 7 kg/m2) recibieron tratamiento con aGLP-1 e intervenciones en el estilo de vida y fueron evaluadas retrospectivamente al inicio y después de 3 meses. A 99 pacientes se les prescribió semaglutida sc, 0,5 mg semanales, con indicación fuera de la ficha técnica para reducción del peso, y se les comparó con 80 pacientes tratados con 3 mg día de liraglutida sc. Se estudió la evolución de los parámetros antropométricos y de composición corporal en ambos grupos. Resultados: las PwO experimentaron una reducción significativa del peso con la semaglutida sc en dosis de 0,5 mg semanales (96,67 ± 20,83 vs. 91,44 ± 19,6 kg; p < 0,01) y la liraglutida en dosis de 3 mg al día (90,73 ± 21,88 vs. 80,13 ± 18,38 kg; p < 0,01). No se observaron diferencias significativas entre los grupos en la cantidad de peso perdida ni en términos de la masa grasa ni de la masa libre de grasa. Conclusión: tanto la semaglutida en dosis de 0,5 mg y como la liraglutida en dosis de 3 mg son tratamientos eficaces y seguros para reducir el peso en las PwO sin impacto negativo sobre la masa magra. Además, en la vida real, las dosis bajas de semaglutida fueron similares a las de 3 mg de liraglutida para reducir el peso corporal a corto plazo.
Fatigue is a frequent and disabling symptom in myelodysplastic syndromes (MDS). There is evidence for the benefit of exercise on fatigue in haematological malignancies, but clinical trials targeting patients with MDS do not exist. A prospective, non-randomized feasibility trial was conducted to assess the safety and efficacy of a home-based exercise intervention in patients with MDS. Exercise schedule contained endurance or strength training in daily turns over 12 weeks. Outcome measures included 6-min walking distance (6-MWD), an ergometer check, strength measurement of lower limb, abdomen and back, quality of life and fatigue. Twenty-one patients (13 male, 8 female) were included. Median age was 66 years (range 29-87). Fifteen patients (71%) continued the program till week 12 (T1), of whom eleven patients met criteria for program completion. There were no adverse events reported due to the intervention. 6-MWD significantly improved from 580m at T0 to 645m at T1 (p<0.05). Fatigue scores did not significantly change over time (MFI: 12.8 vs. 12.3 vs. 11.9; QLQ-C30 fatigue scale: 48.2 vs. 46.7 vs. 47.4). These data provide evidence that an unsupervised outpatient exercise program is feasible and can improve physical capacity. Randomized, controlled studies implementing these interventions are warranted.
Halomonas hydrothermalis strain Slthf2 is a Gram-negative bacterium isolated from low-temperature hydrothermal fluids in South Pacific Ocean vent fields located at 2,580-m depth. Here, we report the complete genome sequence of this strain, which has a genome size of 4.12 Mb, with a GC content of 53.2%.